Cartesian Therapeutics
Clinical trials sponsored by Cartesian Therapeutics, explained in plain language.
A clinical-stage biotech developing RNA cell therapies for autoimmune diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Engineered immune cells take on lupus in tiny trial Results expected Dec 2026 (estimated)
- Could a One-Time cell therapy ease myasthenia gravis? new trial launches Results expected Dec 2026 (estimated) 🚀 Make-or-break
-
Could a One-Time cell therapy ease myasthenia gravis? new trial launches
Disease control OngoingThis phase 3 study tests an experimental treatment called Descartes-08 for adults with generalized myasthenia gravis, a condition causing muscle weakness. The therapy uses modified immune cells (mRNA CAR T-cells) to target the disease. About 100 participants will receive either t…
Phase 3 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Engineered immune cells take aim at myasthenia gravis
Disease control OngoingThis Phase 2 trial is testing an experimental therapy called Descartes-08 for people with generalized myasthenia gravis, a condition that causes muscle weakness. Descartes-08 uses a patient's own immune cells, engineered to target and potentially reduce the harmful immune cells t…
Phase 2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Engineered immune cells take on lupus in tiny trial
Disease control OngoingThis Phase 2 trial is testing a new treatment called Descartes-08 for people with systemic lupus erythematosus (SLE). Descartes-08 uses a patient's own immune cells, modified to target a protein called BCMA, to try to control the disease. Only 6 participants with active lupus des…
Phase 2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC